Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Volunteers to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1817080, Followed by (Part 2), Two-way Crossover Administration of Four Different Doses in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of Concept

Trial Profile

Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Volunteers to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1817080, Followed by (Part 2), Two-way Crossover Administration of Four Different Doses in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of Concept

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs BAY 1817080 (Primary)
  • Indications Cough
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 06 Dec 2018 Planned End Date changed from 17 Jul 2019 to 3 Jul 2019.
    • 06 Dec 2018 Planned primary completion date changed from 5 Jun 2019 to 28 Feb 2019.
    • 08 Nov 2018 Planned End Date changed from 28 Mar 2019 to 17 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top